权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

High-content functional cancer drug testing on micro-cuboidal tumor dissections

微立方体肿瘤解剖的高内涵功能性癌症药物测试

基本信息

批准号：
10025143
负责人：
ALBERT FOLCH
金额：
$ 60.2万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-06 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10025143
关键词：
Address Agonist Antibodies Antitumor Drug Screening Assays Autologous Behavior Bioinformatics Biopsy Breast Cancer Model Breast Cancer Patient CTLA4 gene Cell Death Cells Cellular immunotherapy Clinic Collaborations Collagen Cytotoxic agent Development Devices Diffuse Dissection Drug Combinations Drug Delivery Systems Drug Exposure Ensure Enzyme-Linked Immunosorbent Assay Evaluation Excision Extracellular Matrix Fluorescence Future Gel Glioma Goals Growth Human Hydrogels Immune Immune checkpoint inhibitor Immune system Immunohistochemistry Immunomodulators Immunotherapy In Situ Individual Innate Immune System Interleukin-10 Label Lasers Liquid substance Mammary Neoplasms Methodology Microdissection Microfluidic Microchips Microfluidics Modeling Mouse Mammary Tumor Virus Mus Optics Organoids Patients Pharmaceutical Preparations Pharmacotherapy Phase Polymethyl Methacrylate Preparation Production Reproducibility Retrieval Sampling Shapes Slice Stains T cell therapy T-Cell Activation T-Lymphocyte Testing Tissue Microarray Tissue Viability Tissues Tumor Tissue Tumor-Derived Tumor-infiltrating immune cells Xenograft Model base cancer immunotherapy cancer therapy cell killing cell type cost cytokine design drug development drug response prediction genetic analysis human tissue macrophage malignant breast neoplasm micrography next generation particle personalized cancer therapy preservation prevent programmed cell death ligand 1 programmed cell death protein 1 prototype response screening tumor tumor microenvironment wasting

项目摘要

ABSTRACT The goal of this project is to perform high-content analysis of drug and immunotherapy responses on hundreds of intact, live cultured fragments isolated from a single live tumor biopsy. In recent years, patient-derived tumor “organoids” have shown great promise to predict drug responses for personalized cancer treatment. Immunotherapy, including cellular immunotherapy, represents the next generation of cancer therapy, and many of the relevant drugs act on the local tumor microenvironment (TME). There is a pressing need for functional testing platforms that use human, intact and live tumor tissue to better predict traditional and immunotherapy responses. Such platforms should also retain as much of the native TME as possible. Present high-throughput testing platforms that have some of these features, e.g. based on patient-derived tumor organoids, require a growth step that alters the TME. On the other hand, the micro-dissection of tumor tissue into “spheroids” that contain the TME intact has shown promising responses to immunomodulators on native immune cells. We propose a microfluidic platform that enables drug treatment, exogenous T cell therapy, and high-content analysis using hundreds to thousands of similarly sized, precision-sliced cuboidal micro-tissues (CµTs) produced from a single tumor sample. Here we propose a combination of two methodologies to demonstrate the feasibility of our approach: 1) precision slicing methodology that will produce large numbers of cuboidal micro-tissues (CµTs) from a single tumor biopsy; and 2) microfluidic trapping of the CµTs in a multi-well platform, allowing for drug application to each individual CµT or groups of CµTs. We will be able to obtain several hundred patient-derived CµTs from each tumor resection. The size of the CµTs (initially 400 µm×400 µm×400 µm) will be reproducible and chosen to optimize viability and retention of the TME. As the CµTs are cultured, their cuboidal shape will relax into a more rounded one. We will study the viability of the CµTs and their TME composition as a function of size in various culture conditions, including collagen gels. We will focus on breast cancer immunotherapy using a syngeneic mouse breast tumor model. For this Aim, we will deliver various concentrations and combinations of immunomodulatory drugs, including antibody-based drugs, to breast tumor CµTs in the microfluidic device, and examine the effects on the resident immune system. We will assess cytokine production and use high-content immunohistochemistry and bioinformatics analysis to assess immune cell engagement with different cell types as well as cell death. We will apply the platform to deliver immune checkpoint inhibitors (CTLA4, PD-L1, PD-1) and other immunomodulators (such as IL-10) and examine the effect on the immune state, cell death, and the behavior of resident T cells (activation and localization). In the R33 phase we plan on applying our microfluidic platform to CµTs obtained from breast tumor patients (ongoing collaboration with Dr. V.K. Gadi, Fred Hutch).

摘要